| Name | Title | Contact Details |
|---|---|---|
Frederic Dross |
Vice President of Technology Americas | Profile |
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.
Bioforward is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GangaGen Inc is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InMed Diagnostics is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.